Summary
Anteris Technologies Ltd (Anteris Technologies), formerly Admedus Ltd designs, develops, and commercializes innovative medical devices and technologies with a focus on tissue engineering and immunotherapies. The company's primary activities include conducting clinical trials, securing regulatory approvals, and manufacturing its flagship product, the DurAVR THV, a transcatheter heart valve (THV) for treating aortic stenosis. Anteris also collaborates with v2vmedtech inc to develop a minimally invasive treatment for mitral and tricuspid valve regurgitation. The DurAVR THV, made using Anteris' patented ADAPT anti-calcification tissue technology, is used by healthcare professionals in the treatment of severe aortic stenosis. The company's products are distributed globally. The company's target markets include Australia, Europe, the US, Canada, Singapore, Malaysia, India, Hong Kong, and the Middle East. Anteris Technologies is headquartered in Brisbane, Queensland, Australia.This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Anteris Technologies Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Anteris Technologies Ltd Company Overview
- Anteris Technologies Ltd Company Snapshot
- Anteris Technologies Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Anteris Technologies Ltd - Pipeline Analysis Overview
- Business Description
- Anteris Technologies Ltd - Key Facts
- Anteris Technologies Ltd - Major Products and Services
- Anteris Technologies Ltd Pipeline Products by Development Stage
- Anteris Technologies Ltd Ongoing Clinical Trials by Trial Status
- Anteris Technologies Ltd Pipeline Products Overview
- ADAPT - Carotid Artery Repair
- ADAPT - Carotid Artery Repair Product Overview
- ADAPT - Dura Mater Repair
- ADAPT - Dura Mater Repair Product Overview
- ADAPT - Half Pipe Conduit
- ADAPT - Half Pipe Conduit Product Overview
- ADAPT - Hernia Repair
- ADAPT - Hernia Repair Product Overview
- ADAPT - Jugular Vein
- ADAPT - Jugular Vein Product Overview
- ADAPT - Pediatric Leaflets
- ADAPT - Pediatric Leaflets Product Overview
- ADAPT - Samurai
- ADAPT - Samurai Product Overview
- ADAPT - Whole Vascular Tissue
- ADAPT - Whole Vascular Tissue Product Overview
- ADAPT Based Device - Orthopedics
- ADAPT Based Device - Orthopedics Product Overview
- ComASUR Transfemoral Delivery System
- ComASUR Transfemoral Delivery System Product Overview
- DurAVR Leaflet Repair (RP)
- DurAVR Leaflet Repair (RP) Product Overview
- DurAVR THV System
- DurAVR THV System Product Overview
- DurAVR THV System Clinical Trial
- GyneCel
- GyneCel Product Overview
- VClip
- VClip Product Overview
- Anteris Technologies Ltd - Key Competitors
- Anteris Technologies Ltd - Key Employees
- Anteris Technologies Ltd - Key Employee Biographies
- Anteris Technologies Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Anteris Technologies Ltd, Recent Developments
- Oct 17, 2024: Anteris Receives $1.4m R&D Tax Refund
- Jul 01, 2024: Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study
- Jun 20, 2024: DurAVR THV First-in-Human Data Confirms Optimal Valve Positioning with the ComASUR Delivery System
- Jun 18, 2024: Anteris Provides Update on Pivotal Trial Submission US FDA has provided positive feedback on key elements of the study design
- Jun 13, 2024: Anteris Provides Update on DurAVR THV Valve-In-Valve Experience Presented at New York Valves 2024
- Jun 11, 2024: Anteris Provides Data Update on First in Human Study of DurAVR THV Presented at New York Valves 2024
- Aug 14, 2023: Further clinical success for Anteris Technologies’ biomimetic heart valve
- Aug 09, 2023: Anteris’ starts US trial for DurAVR transcatheter heart valve
- Jul 31, 2023: Anteris Technologies Announces First Successful Implantation of DurAVR THV in a Valve-in-Valve Procedure
- Jun 13, 2023: Latest Patient Group Show Best Results to Date at 30 Days
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Anteris Technologies Ltd Pipeline Products and Ongoing Clinical Trials Overview
- Anteris Technologies Ltd Pipeline Products by Equipment Type
- Anteris Technologies Ltd Pipeline Products by Indication
- Anteris Technologies Ltd Ongoing Clinical Trials by Trial Status
- Anteris Technologies Ltd, Key Facts
- Anteris Technologies Ltd, Major Products and Services
- Anteris Technologies Ltd Number of Pipeline Products by Development Stage
- Anteris Technologies Ltd Pipeline Products Summary by Development Stage
- Anteris Technologies Ltd Ongoing Clinical Trials by Trial Status
- Anteris Technologies Ltd Ongoing Clinical Trials Summary
- ADAPT - Carotid Artery Repair - Product Status
- ADAPT - Carotid Artery Repair - Product Description
- ADAPT - Dura Mater Repair - Product Status
- ADAPT - Dura Mater Repair - Product Description
- ADAPT - Half Pipe Conduit - Product Status
- ADAPT - Half Pipe Conduit - Product Description
- ADAPT - Hernia Repair - Product Status
- ADAPT - Hernia Repair - Product Description
- ADAPT - Jugular Vein - Product Status
- ADAPT - Jugular Vein - Product Description
- ADAPT - Pediatric Leaflets - Product Status
- ADAPT - Pediatric Leaflets - Product Description
- ADAPT - Samurai - Product Status
- ADAPT - Samurai - Product Description
- ADAPT - Whole Vascular Tissue - Product Status
- ADAPT - Whole Vascular Tissue - Product Description
- ADAPT Based Device - Orthopedics - Product Status
- ADAPT Based Device - Orthopedics - Product Description
- ComASUR Transfemoral Delivery System - Product Status
- ComASUR Transfemoral Delivery System - Product Description
- DurAVR Leaflet Repair (RP) - Product Status
- DurAVR Leaflet Repair (RP) - Product Description
- DurAVR THV System - Product Status
- DurAVR THV System - Product Description
- DurAVR THV System - A Pivotal Study to Evaluate the Efficacy of DurAVR THV System for the Treatment Aortic Stenosis
- DurAVR THV System - DurAVR THV System in a Valve-in-Valve Procedure: A First Successful Implantation in Humans
- DurAVR THV System - DurAVR THV System: European Early Feasibility Study
- DurAVR THV System - Use of DurAVR THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
- DurAVR THV System - Use of DurAVR THV System in Subjects with Severe Aortic Stenosis: First In Human Study
- GyneCel - Product Status
- GyneCel - Product Description
- VClip - Product Status
- VClip - Product Description
- Anteris Technologies Ltd, Key Employees
- Anteris Technologies Ltd, Key Employee Biographies
- Anteris Technologies Ltd, Subsidiaries
- Glossary
- Anteris Technologies Ltd Pipeline Products by Equipment Type
- Anteris Technologies Ltd Pipeline Products by Development Stage
- Anteris Technologies Ltd Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biotron Ltd
- Nexstim Plc
- Medtronic Australasia Pty Ltd
- Benitec Biopharma Inc
- Medsonix Inc
